Phase 2
Completed N=146
A Study to Test the Effectiveness and Safety of MK0893 in Combination With Other Drugs Used to Treat Type 2 Diabetes (0893-015)
Source: ClinicalTrials.gov NCT00631488 ↗Enrolled (actual)
146
Serious AEs
0.0%
Results posted
Feb 2012
Primary outcomePrimary: Change From Baseline (BL) to Week 4 in 24-hour Weighted Mean Glucose (WMG) Levels — -85.7; -117.4; -99.6 mg/dL — p=0.002
Summary
This study will test the effectiveness and safety of treatment with MK-0893 in combination with other drugs commonly used to treat type 2 diabetes for a duration up to 13 weeks.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change From Baseline (BL) to Week 4 in 24-hour Weighted Mean Glucose (WMG) Levels |
-85.7; -117.4; -99.6 | 0.002 sig |
| SECONDARY Change From BL to Week 4 in Fasting Plasma Glucose (FPG) |
-73.7; -101.9; -82.8 | 0.050 |
| SECONDARY Change From BL to Week 4 in 2-hr Glucose Area Under The Curve (AUC) |
-187.7; -254.9; -210.3 | 0.056 |
| SECONDARY Change From BL to Week 4 in the 2-Hour Total GLP-1 Total AUC |
7.4; 16.4; 3.2 | 0.001 sig |
| SECONDARY Change From BL to Week 4 in the 2-Hour Active GLP-1 Total AUC |
11.0; 6.3; 17.6 | <0.001 sig |
Eligibility Criteria
Inclusion Criteria
- Participants who have Type 2 Diabetes Mellitus, with suboptimal glucose control, while either not on AHA (antihyperglycemic agent) therapy or on monotherapy or on low-dose combination therapy
Exclusion Criteria
- Participants have a history of Type 1 Diabetes Mellitus
- Participants taking insulin or thiazolidinediones (TZDs: peroxisome proliferator-activated receptor [PPAR]-gamma agonists)
- Participants who have a contraindication to metformin or sitagliptin
Data sourced from ClinicalTrials.gov (NCT00631488). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.